Brad Spellberg at 9th Anti-infectives Partnering summit July 9, 2012 California
Brad Spellberg, Associate Professor of Medicine at UCLA Medical Center will give a keynote presentation on "The Future of Antibiotic R&D" at the 9th Anti-Infectives Partnering and Deal-making Conference taking place on July 9-10, 2012 in San Francisco, CA.
- San Diego, CA (1888PressRelease) May 10, 2012 - Ever-rising antibiotic resistance continues to plague public health systems all over the world. Meanwhile, new discovery and development of antibiotics continues to face scientific, regulatory, and economic challenges. What does the future hold? The medical need for new antibiotics will continue to worsen. Rapid diagnostics, changes in the regulatory landscape, public private partnerships, improved biological technologies, and expansion of international markets will have major impact on what antibiotics are developed and how.
Dr. Spellberg will:
- Review the unmet medical need of antibiotics
- Discuss recent economic and legislative developments
- Discuss current and future regulatory environments
- Review the concept of public private partnerships
Dr. Spellberg is an Associate Professor of Medicine at the David Geffen School of Medicine at UCLA and the Harbor-UCLA Medical Center. He is also Associate Program Director for the Internal Medicine Residency Training Program at Harbor-UCLA Medical Center. Dr. Spellberg has worked with the Infectious Diseases Society of America (IDSA) to attempt to bring attention to the problems of increasing drug resistance and decreasing new antibiotics. His research regarding new drug development has been cited extensively in medical literature and on Capitol Hill. He is a Fellow in the IDSA and Co-Chair of the IDSA's Antimicrobial Availability Task Force (AATF). As a member of the AATF, he has first-authored numerous IDSA position papers and review articles relating to public policy of antibiotic resistance and antibiotic development. Finally, Dr. Spellberg is the author of Rising Plague, which he wrote to inform and educate the public about the crisis in antibiotic resistant infections and lack of antibiotic development.
GTC's 9th Anti-infectives Partnering and Deal-Making Conference will contribute to the on-going battle against the ever-changing infectious threats by having experts with direct experiences in the field discuss a wide variety of topics on infectious diseases. The agenda also allows time for networking and opportunities to interface with speakers and fellow delegates in a collegial setting. Previous GTC conferences have been catalytic to several successful partnerships and in 2012 we expect this trend to continue.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam